

2025 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Alexis K. Kuhn, PharmD, BCOP	Peer Reviewer	1. Jazz Pharmaceuticals, Sanofi Genzyme	1. Advisory Board Member	All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Alison Carulli, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Alyssa Donadio, PharmD, BCPS, BCOP	Planning Committee	1. Genentech	1. Non-CE Consulting	All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.
Amanda Strommen, PharmD, BCOP	Planning Committee	1. Eisai	1. Employment as a Medical Science Liaison	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Eisai ended in May 2023 All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.
Amber Clemmons, PharmD, BCOP, FHOPA	Faculty	No relevant financial disclosures	N/A	N/A
Andrew Artz, MD	Faculty	1. AstraZeneca, Daiichi Sankyo	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> AstraZeneca ended in July 2023 Daiichi Sankyo ended in November 2024 Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Arpita Ghandi, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Ashley Smeaton, MHA	TFF Staff	No relevant financial disclosures	N/A	N/A

2025 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Bhagirathbhai Dholaria, MD	Peer Reviewer	<p>1. ADC Therapeutics, Arivan Research, Caribou, F. Hoffmann-La Roche AG, Gilead, GSK, Janssen, MJH BioScience, Pierre Fabre</p> <p>2. Adicet, Allovir, Angiocrine, Atara, BMS, Janssen, MEI, Moleucar Template, Orcabio, Wugen</p> <p>3. Kura Oncology, Syndax Pharmaceuticals</p>	<p>1. Non-CE Consulting</p> <p>2. Contract Research</p> <p>3. Stock ownership of a publicly traded company</p>	All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Binni Kunvarjee, PharmD, BCOP	Faculty	1. Wolters Kluwer	1. Non-CE Consulting	Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Breana Goscicki, PharmD, BCPPS	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Cameron Ninos, PharmD, BCOP	Faculty	1. Eli Lilly	1. Stock ownership of a	Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not

2025 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
			publicly traded company	commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Cham Nguyen, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Christopher Cornett, PharmD	Planning Committee	No relevant financial disclosures	N/A	N/A
Elizabeth DiMaggio, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Erika Wass, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Erin Goodell, PharmD, BCOP	Planning Committee	No relevant financial disclosures	N/A	N/A
Frank Oley Jr, PharmD, MBA, BCOP	Planning Committee	No relevant financial disclosures	N/A	N/A
Frank P. Tverdek, PharmD	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Gianni Scappaticci, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Haedyn Smith	ASTCT Staff	No relevant financial disclosures	N/A	N/A
Hanna Bailey, PharmD, BCOP	Peer Reviewer	1. BiolineRX	1. Advisory Board participant	All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Heather Tarbox, MPH	TFF Staff	No relevant financial disclosures	N/A	N/A
Hemalatha Rangarajan, MD	Faculty	1. Medexus Treosufan	1. One-time consultancy	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Medexus Treosufan ended in June 2024 Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not

2025 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
				commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Ila Saunders, PharmD, BCOP	Faculty	1. Sanofi	1. Advisory Board, Speaker Honoraria	Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
J. Ryan Shaw, PharmD, BCPS, BCOP	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Jason Ernstberger, PharmD	Faculty	No relevant financial disclosures	N/A	N/A
Jeanne Noonan McCarthy-Kaiser	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Jeff Kaiser, PharmD	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Jennifer Collins, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Jinjoo Kang, PharmD, BCPS	Planning Committee	No relevant financial disclosures	N/A	N/A
Julie Guglielmo, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Karen Sweiss, PharmD	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Katie Karkowski, PharmD, BCOP	Planning Committee	No relevant financial disclosures	N/A	N/A
Kelsea Seago, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Kendall Shultes, PharmD, BCOP	Planning Committee Chair	1. Projects in Knowledge, Oncology Times	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Projects in Knowledge ended in October 2023

2025 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
				All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.
Kristina Nelson, PharmD	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Lauren Ice, PharmD, BCOP	Planning Committee	1. Wolters Kluwer	1. Non-CE Consulting	All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA	Faculty, Peer Reviewer	No relevant financial disclosures	N/A	N/A
Lily Yan, PharmD, BCOP	Planning Committee	No relevant financial disclosures	N/A	N/A
Lindsay Orton, PharmD, BCOP	Planning Committee	No relevant financial disclosures	N/A	N/A
Liz Stockton	ASTCT Staff	No relevant financial disclosures	N/A	N/A
Mallori Anderson, PharmD	Planning Committee	No relevant financial disclosures	N/A	N/A
Marco Ruiz, MD, MPH	Faculty, Peer Reviewer	1. Johnson and Johnson 2. Johnson and Johnson	1. Non-CE Consulting 2. Non-CE Speakers Bureau	<p>The following financial relationships have been mitigated by:</p> <ul style="list-style-type: none"> The non-CE speakers bureau relationship ended with Johnson and Johnson September 2024 <p>All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.</p> <p>Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not</p>

2025 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
				commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Mariam Nawas, MD	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Mary Catherine (Catie) Cash, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Mary McGann, PharmD, BCOP	Faculty, Planning Committee, Peer Reviewer	1. Sanofi	1. Non-CE Consulting	<p>The following financial relationships have been mitigated by:</p> <ul style="list-style-type: none"> Sanofi ended in February 2024 <p>All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.</p> <p>Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Misty Lamprecht, MS, APRN-CNS, AOCN, BMTCN	Planning Committee	No relevant financial disclosures	N/A	N/A
Molly Gallogly, MD, PhD	Peer Reviewer	1. Eli Lilly, MJH Life Sciences 2. Incyte	1. Non-CE Speakers Bureau 2. Advisory Board	All final review decisions concerning content, learning objectives, and evaluation questions were made by non-conflicted members of the Planning Committee.
Molly Schiffer, PharmD, BCOP	Planning Committee	No relevant financial disclosures	N/A	N/A
Morgan Belling, PharmD, BCOP	Planning Committee	No relevant financial disclosures	N/A	N/A

2025 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Natalie Brumwell, PharmD, BCOP	Planning Committee	No relevant financial disclosures	N/A	N/A
Nicole Soriano, PharmD	Planning Committee	1. Genmab	1. Non-CE Consulting	The following financial relationship has been mitigated by: <ul style="list-style-type: none"> Genmab ended in March 2024 All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.
Rachel Phelan, MD, MPH	Peer Reviewer	1. Bluebird Bio	1. Advisory Board Participation	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> Bluebird Bio ended in August 2023 All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.
Rebecca Gonzalez, PharmD, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Rebecca LaRue, PharmD	Planning Committee	No relevant financial disclosures	N/A	N/A
Samuel Goldfarb, MD	Faculty	No relevant financial disclosures	N/A	N/A
Sara Leidy, PharmD	Planning Committee	No relevant financial disclosures	N/A	N/A
Susie Long, PharmD	Faculty, Planning Committee	1. McKesson Corporation	1. Non-CE Consulting	All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee. Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.

2025 ASTCT Fundamentals of HCT Virtual Training Course - Disclosures

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Suzanne Gettys, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Tatjana Grgic, PharmD, BCOP, CPP	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Teresa Rushing, PharmD, BCPS, BCOP	Faculty	No relevant financial disclosures	N/A	N/A
Terri Lynn Shigle, PharmD, BCPS, BCOP	Peer Reviewer	No relevant financial disclosures	N/A	N/A
Tiba Al Sagheer, PharmD, BCOP, BCACP	Peer Reviewer	1. Bristol Myers Squibb, Eli Lilly	1. Non-CE Consulting	<p>The following financial relationships have been mitigated by:</p> <ul style="list-style-type: none"> ▪ BMS ended in January 2023 ▪ Eli Lilly ended in April 2024 <p>All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted members of the Planning Committee.</p>
Vera Pervitsky, PharmD, BCOP, BCPS	Planning Committee	No relevant financial disclosures	N/A	N/A
Vinita B. Pai, PharmD	Peer Reviewer	No relevant financial disclosures	N/A	N/A